Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1β after live yellow fever vaccination

Por Hacker, U T, Erhardt, S, Tschöp, K, Jelinek, T, Endres, S
Publicado em 2001

Developmentally regulated Drosophila gene family encoding the fork head domain.

Por Häcker, U, Grossniklaus, U, Gehring, W J, Jäckle, H
Publicado em 1992

The Drosophila fork head domain protein crocodile is required for the establishment of head structures.

Por Häcker, U, Kaufmann, E, Hartmann, C, Jürgens, G, Knöchel, W, Jäckle, H
Publicado em 1995

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

Por Hofheinz, R.-D., Ronellenfitsch, U., Kubicka, S., Falcone, A., Burkholder, I., Hacker, U. T.
Publicado no Gastroenterol Res Pract (2016)

Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis.

Por Hacker, U T, Gomolka, M, Keller, E, Eigler, A, Folwaczny, C, Fricke, H, Albert, E, Loeschke, K, Endres, S
Publicado em 1997

Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours

Por Coutelle, O, Schiffmann, L M, Liwschitz, M, Brunold, M, Goede, V, Hallek, M, Kashkar, H, Hacker, U T
Publicado no Br J Cancer (2015)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

Por Hoehler, T, von Wichert, G, Schimanski, C, Kanzler, S, Moehler, M H, Hinke, A, Seufferlein, T, Siebler, J, Hochhaus, A, Arnold, D, Hallek, M, Hofheinz, R, Hacker, U T
Publicado em 2013

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

Por Schultheis, B., Folprecht, G., Kuhlmann, J., Ehrenberg, R., Hacker, U. T., Köhne, C. H., Kornacker, M., Boix, O., Lettieri, J., Krauss, J., Fischer, R., Hamann, S., Strumberg, D., Mross, K. B.
Publicado em 2013

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition

Por Schiffmann, L M, Brunold, M, Liwschitz, M, Goede, V, Loges, S, Wroblewski, M, Quaas, A, Alakus, H, Stippel, D, Bruns, C J, Hallek, M, Kashkar, H, Hacker, U T, Coutelle, O
Publicado no Br J Cancer (2017)

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

Por Goede, V, Coutelle, O, Neuneier, J, Reinacher-Schick, A, Schnell, R, Koslowsky, T C, Weihrauch, M R, Cremer, B, Kashkar, H, Odenthal, M, Augustin, H G, Schmiegel, W, Hallek, M, Hacker, U T
Publicado em 2010